Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
44.13%
0%
44.13%
6 Months
47.68%
0%
47.68%
1 Year
53.71%
0%
53.71%
2 Years
122.54%
0%
122.54%
3 Years
-17.18%
0%
-17.18%
4 Years
-11.77%
0%
-11.77%
5 Years
71.51%
0%
71.51%
ChemoMetec A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.28%
EBIT Growth (5y)
25.09%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.94
Tax Ratio
23.29%
Dividend Payout Ratio
65.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
82.06%
ROE (avg)
35.33%
Valuation key factors
Factor
Value
P/E Ratio
61
Industry P/E
Price to Book Value
16.93
EV to EBIT
46.76
EV to EBITDA
44.65
EV to Capital Employed
33.03
EV to Sales
22.32
PEG Ratio
1.66
Dividend Yield
2.14%
ROCE (Latest)
70.62%
ROE (Latest)
27.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
442.30
427.20
3.53%
Operating Profit (PBDIT) excl Other Income
242.40
215.30
12.59%
Interest
1.10
1.50
-26.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
178.70
159.50
12.04%
Operating Profit Margin (Excl OI)
516.70%
471.80%
4.49%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is 3.53% vs 51.97% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is 12.04% vs 80.43% in Jun 2022
About ChemoMetec A/S 
ChemoMetec A/S
Pharmaceuticals & Biotechnology
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.






